Ernexa Therapeutics Inc. (ERNA) Form 8-K — Jun 26, 2026
On June 22, 2026, Sandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., notified the company of her resignation effective July 3, 2026. The company stated that her resignation was not due to any disagreement regarding operations, policies, or practices. Ms. Gurrola has agreed to provide part-time transition assistance of up to 10 hours per week through the filing of the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
Price after filing
Close on the filing date to close N calendar days later (from $7.40). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.